Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer

Cancer Medicine

Volumn 5, Issue 12, 2016, Pages 3572-3578

  Pancewicz Wojtkiewicz, Joanna ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Epidermal growth factor receptor; non small cell lung cancer; Notch; tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; NOTCH INHIBITOR; NOTCH RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; DRUG EFFICACY; EGFR GENE; GENE EXPRESSION; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; LUNG CARCINOGENESIS; LYMPH NODE METASTASIS; NON SMALL CELL LUNG CANCER; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANIMAL; DRUG EFFECTS; LUNG TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 85007569807     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.944     Document Type: Review

References (50)

1. Ciardiello, F., and G. Tortora. 2008. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358:1160–1174.
2. Ciardiello, F., and G. Tortora. 1998. Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. Clin. Cancer Res. 4:821–828.
3. Lynch, T. J., D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2129–2139.
4. Pao, W., and V. A. Miller. 2005. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23:556–2568.
5. Cheng, L., and D. Zhang. 2008. Molecular genetic pathology. Humana Press/Springer, New York, NY.
6. Reade, C. A., and A. K. Ganti. 2009. EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biogeosciences 3:215–224.
7. Cheng, L., S. Zhang, R. Alexander, Y. Yao, G. T. MacLennan, C. X. Pan, et al. 2011. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncol. 7:519–541.
8. Lopes, G. L., E. F. Vattimo, and G. de Castro Junior. 2015. Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer. J Bras. Pneumol. 41:365–375.
9. Tsiambas, E., V. Ragos, A. Y. Lefas, S. N. Georgiannos, D. Grapsa, E. Patsouris, et al. 2015. Chromosome 7 deregulation in non-small cell lung carcinoma molecular landscape. J BUON 20:1635–1639.
10. Winther-Larsen, A., P. H. Nissen, K. R. Jakobsen, C. Demuth, B. S. Sorensen, and P. Meldgaard. 2015. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib. Lung Cancer 90:314–320.
11. Dahabreh, I. J., H. Linardou, F. Siannis, P. Kosmidis, D. Bafaloukos, and S. Murray. 2010. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 16:291–303.
12. Hirsch, F. R., R. S. Herbst, C. Olsen, K. Chansky, J. Crowley, K. Kelly, et al. 2008. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J. Clin. Oncol. 26:3351–3357.
13. Cappuzzo F., F. R. Hirsch, E. Rossi, S. Bartolini, G. L. Ceresoli, L. Bemis, et al. 2005. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl Cancer Inst. 97:643–655.
14. Sholl, L. M., A. John Iafrate, Y. P. Chou, M. T. Wu, Y. G. Goan, L. Su, et al. 2007. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod. Pathol. 20:1028–1035.
15. Tsao, M. S., A. Sakurada, J. C. Cutz, C. Q. Zhu, S. Kamel-Reid, J. Squire, et al. 2005. Erlotinib in lung cancer – molecular and clinical predictors of outcome. N. Engl. J. Med. 353:133–144.
16. Cappuzzo, F., C. Ligorio, P. A. Jänne, L. Toschi, E. Rossi, R. Trisolini, et al. 2007. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-AKT-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J. Clin. Oncol. 25:2248–2255.
17. Li, J., X. F. Jia, J. Liu, J. J. Liu, and H. B. Zhao. 2015. Relationship of EGFR DNA methylation with the severity of non-small cell lung cancer. Genet. Mol. Res. 14:11915–11923.
18. Endoh, H., Y. Ishibashi, E. Yamaki, T. Yoshida, T. Yajima, H. Kimura, et al. 2009. Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. Lung Cancer 63:241–246.
19. Hijiya, N., M. Miyawaki, K. Kawahara, S. Akamine, K. Tsuji, J. Kadota, et al. 2008. Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. Hum. Pathol. 39:316–323.
20. Pancewicz, J., and C. Nicot. 2011. Current views on the role of Notch signaling and the pathogenesis of human leukemia. BMC Cancer 11:502.
21. Liu, N., J. Zhang, and C. Ji. 2013. Ankyrin/CDC10 repeats (ANK), necessary for protein-protein interactions. Biomark. Res. 1:23.
22. Andersson, E. R., R. Sandberg, and U. Lendahl. 2011. Notch signaling: simplicity in design, versatility in function. Development 138:3593–3612.
23. Yamaguchi, H., S. S. Chang, J. L. Hsu, and M. C. Hung. 2014. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene 33:1073–1081.
24. Brizzi, M. F., and P. Defilippi. 2013. Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology. Transl. Lung Cancer Res. 2:466–469.
25. Yuan, X., H. Wu, H. Xu, N. Han, Q. Chu, S. Yu, et al. 2015. Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. Sci. Rep. 5:10338.
26. Chen, Y., M. A. De Marco, I. Graziani, A. F. Gazdar, P. R. Strack, L. Miele, et al. 2007. Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res. 67:7954–7959.
27. Konishi, J., K. S. Kawaguchi, H. Vo, N. Haruki, A. Gonzalez, D. P. Carbone, et al. 2007. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 67:8051–8057.
28. Westhoff, B., I. N. Colaluca, G. D'Ario, M. Donzelli, D. Tosoni, S. Volorio, et al. 2009. Alterations of the Notch pathway in lung cancer. Proc. Natl Acad. Sci. USA 106:22293–22298.
29. Doroquez, D. B., and I. Rebay. 2006. Signal integration during development: mechanisms of EGFR and Notch pathway function and cross-talk. Crit. Rev. Biochem. Mol. Biol. 41:339–385.
30. Aita, M., G. Fasola, C. Defferrari, A. Brianti, M. G. Bello, A. Follador, et al. 2008. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit. Rev. Oncol. Hematol. 68:183–196.
31. Adamo, V., T. Franchina, B. Adamo, N. Denaro, P. Gambadauro, G. Chiofalo, et al. 2009. Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives. Cancer Biol. Ther. 8:206–212.
32. Scagliotti, G., and R. Govindan. 2010. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist 15:436–446.
33. Pennell, N. A., and T. J. Jr Lynch. 2009. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14:399–411.
34. Xie, M., C. S. He, S. H. Wei, and L. Zhang. 2013. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Eur. J. Cancer 49:3559–3572.
35. Arasada, R. R., J. M. Amann, M. A. Rahman, S. S. Huppert, and D. P. Carbone. 2014. EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling. Cancer Res. 74:5572–5584.
36. Konishi, J., F. Yi, X. Chen, H. Vo, D. P. Carbone, and T. P. Dang. 2010. Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. Oncogene 29:589–596.
37. Kolev, V., A. Mandinova, J. Guinea-Viniegra, B. Hu, K. Lefort, C. Lambertini, et al. 2008. EGFR signaling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat. Cell Biol. 10:902–911.
38. Purow, B. W., T. K. Sundaresan, M. J. Burdick, B. A. Kefas, L. D. Comeau, M. P. Hawkinson, et al. 2008. Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis 29:918–925.
39. Giannopoulou, E., A. Nikolakopoulos, D. Kotsirilou, A. Lampropoulou, S. Raftopoulou, E. Papadimitriou, et al. 2015. Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells. J. Biomed. Sci. 22:98.
40. Choi, K., Y. H. Ahn, D. L. Gibbons, H. T. Tran, C. J. Creighton, L. Girard, et al. 2009. Distinct biological roles for the Notch ligands Jagged-1 and Jagged-2. J. Biol. Chem. 284:17766–17774.
41. Russo, A., T. Franchina, G. R. Ricciardi, A. Picone, G. Ferraro, M. Zanghì, et al. 2015. A decade of EGFR inhibition in EGFR-mutated non- small cell lung cancer (NSCLC): old successes and future perspectives. Oncotarget 6:26814–26825.
42. Purow, B. 2012. Notch inhibition as a promising new approach to cancer therapy. Adv. Exp. Med. Biol. 727:305–319.
43. Luistro, L., W. He, M. Smith, K. Packman, M. Vilenchik, D. Carvajal, et al. 2009. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res. 69:7672–7680.
44. Yang, M. H., Y. S. Zang, H. Huang, K. Chen, B. Li, G. Y. Sun, et al. 2014. Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis. Curr. Cancer Drug Targets 14:557–566.
45. Chonan, M., N. Narita, and T. Tominaga. 2016. Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports. BMC Res. Notes 9:2.
46. Protsenko, S. A., and A. V. Rudakova. 2015. Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis. Vopr. Onkol. 61:676–680.
47. Liu, L. L., F. Li, W. Pao, and F. Michor. 2015. Dose-dependent mutation rates determine optimum erlotinib dosing strategies for EGFR mutant non-small cell lung cancer patients. PLoS ONE 10:11.
48. Bhardwaj, B., S. Revannasiddaiah, H. Bhardwaj, S. Balusu, and A. Shwaiki. 2016. Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma. Ann. Transl. Med. 4:50.
49. Hu, Y., X. Z. Dong, X. Liu, P. Liu, and Y. B. Chen. 2016. Enhanced antitumor activity of cetuximab in combination with the jak inhibitor CYT387 against non-small-cell lung cancer with various genotypes. Mol. Pharm. 13:689–697.
50. Gold, K. A., L. A. Byers, Y. H. Fan, J. Fujimoto, W. H. Tse, J. Jack Lee, et al. 2013. A phase I/II trial combining erlotinib with gamma secretase inhibitor RO4929097 in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 31(Suppl): abstr 8104.